Showing results (231-240 of 670) with videos related to
Sort By:
Pageof 67
Comptes Rendus Des Seances De L'Academie Des Sciences. Serie III, Sciences De La Vie|May 11, 1981
[Modification of the antigenicity of the serum thymic factor (thymulin) by zinc]J M Pleau, M Dardenne, J F BachProstaglandins|April 1, 1988
In vitro inhibition of prostaglandin production by azathioprine and 6-mercaptopurineF Homo-Delarche, J F Bach, M DardenneClinical and Experimental Immunology|August 1, 1989
In vitro and in vivo action of cyclosporin A on the induction of human interleukin-2 receptor alpha and beta chainsS Caillat-Zucman, L Chatenoud, J F BachClinical Pharmacokinetics|November 1, 1993
Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumoursP Chanson, J Timsit, A G HarrisAnnals of the New York Academy of Sciences|February 28, 1975
Regulation of theta-antigen expression by agents altering cyclic AMP level and by thymic factorM A Bach, C Fournier, J F BachEuropean Journal of Immunology|February 1, 1980
Evidence of the presence in normal serum of a carrier of the serum thymic factor (FTS)M Dardenne, J M Pléau, J F BachJournal of Autoimmunity|April 1, 1992
Epstein-Barr virus serology and isoelectrofocusing pattern of serum immunoglobulins in cyclosporin or placebo-treated type I diabeticsG Feutren, G de The, J F BachHuman Immunology|July 31, 1998
HLA class II-associated predisposition to insulin-dependent diabetes mellitus in a Polish populationM Krokowski, J Bodalski, A Bratek, et al.Diabetologia|April 25, 2012
Zinc transporter (ZnT)8(186-194) is an immunodominant CD8+ T cell epitope in HLA-A2+ type 1 diabetic patientsM Scotto, G Afonso, E Larger, et al.Presse Medicale (Paris, France : 1983)|December 18, 1993
[Octreotide, analog of somatostatin. Pharmacological properties and therapeutic applications in pituitary endocrine tumors]P Chanson, J Timsit, A G HarrisPageof 67